Navigation Links
Data on VIVUS' QNEXA to be Presented in Six Posters at The Obesity Society's Annual Meeting
Date:10/7/2010

ase Phentermine/Topiramate Improves Plasma Alanine Transaminase Concentrations (Abstract # 212894; Poster # 496-P)Presenter:

Ronette L. Kolotkin, PhDAuthors:

Kolotkin, Peterson, GaddeTitle:

Improvements in Quality of Life With Low-Dose, Controlled-Release Phentermine/Topiramate in Overweight/Obese Subjects (Abstract # 212896; Poster # 493-P)About QNEXA Controlled Release CapsulesQNEXA [kyoo-nek-suh] is an investigational drug being developed to address weight loss, type 2 diabetes and obstructive sleep apnea. QNEXA is a once-a-day, proprietary, oral, controlled-release formulation of low-dose phentermine and topiramate, which together decrease appetite and increase satiety (the sense of feeling full), the two main mechanisms that impact eating behavior. In phase 2 and 3 clinical data to date, patients taking QNEXA have demonstrated statistically significant weight loss, glycemic control, and improvement in cardiovascular risk factors, when used in combination with a diet and lifestyle modification program.

VIVUS submitted a New Drug Application (NDA) to the FDA in December 2009 seeking approval of QNEXA for the treatment of obesity, including weight loss and maintenance of weight loss, in patients who are obese or overweight with co-morbidities such as hypertension, type 2 diabetes, dyslipidemia or central adiposity. An action date has been set for October 28, 2010.

About ObesityApproximately one-third of American adults (more than 72 million people) are obese, and many more are overweight with co-morbidities. Obesity is a chronic condition defined by having excess body fat. Obesity significantly increases the risk of developing many different diseases and health conditions, including type 2 diabetes, hypertension, metabolic syndrome, cardiovascular disease, some cancers and osteoarthritis. According to a report in The Lancet in 2009, morbid obesity shortens life expectancy by approximately 10 years, an
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. VIVUS Reports First Quarter 2009 Financial Results and Highlights
2. Data on VIVUS Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting
3. VIVUS to Present at the Needham and Company Life Sciences Conference
4. VIVUS to Present at the Canaccord Adams 29th Annual Global Growth Conference
5. VIVUS to Present at Four Upcoming Healthcare Conferences
6. VIVUS Announces Positive Results From Two Phase 3 Studies; Obese Patients on Qnexa Achieve Average Weight Loss up to 14.7% and Significant Improvements in Co-Morbidities
7. VIVUS Reports Third Quarter 2009 Highlights and Financial Results
8. VIVUS to Present at Two Upcoming Investor Conferences
9. VIVUS to Present at Four Upcoming Investor Conferences
10. Vascular Biogenics Ltd. Presented With the Frost & Sullivan 2008 European Gene Expression Targeting Platform Technology Innovation Award
11. ApoA-I Data Presented at European Society of Cardiology Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014 The largest international professional organization ... and therapeutic derivatives thereof has endorsed an educational ... about the challenges of adulterated herb and botanical ... The Society for Medicinal Plant and ...
(Date:1/14/2014)... 14, 2014 In recent years, growing ... methods in product development and promotion has led to ... mistrust, fueled by concerns about the insidious impact of ... of spectacular fines to the world’s biggest pharmas for ...
(Date:1/14/2014)... 2014   Kinaxis ®, provider of RapidResponse ®, a ... operations planning ( S&OP ) service, is proud to be ... will be held at the Hilton San Diego Bayfront, January ... Elisabeth Kaszas , Director of Supply Chain at Amgen, ...
(Date:1/14/2014)... During the 1600’s through the 1800’s doctors contributed ... In this time period, doctors did not know that they ... the death of vulnerable patients. In the same way, medical ... be unwittingly transmitting herpes viruses to their patients. The CBCD ...
Breaking Biology Technology:World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3
... May 19 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ... Quill(TM) SRS wound closure product line is now available ... at https://ecommerce.angiotech.com/Main/Home.aspx . The Quill SRS products are ... Polydioxanone (PDO), MONODERM(TM), Nylon and Polypropylene product lines. , ...
... with Novel Mode of ActionMOUNTAIN VIEW, Calif., May ... that data from the company,s PROTECT-1 (the Prospective ... Phase II/III clinical trial of Traficet-EN(TM) (CCX282-B) in ... in an oral session at the upcoming 2009 ...
... -- Leading pharmaceutical and biotech,companies are drawing on ... enhance their R&D productivity, leverage academic,insights and diversify ... a population,base that is representative of key Asian ... companies to test and develop new solutions for,Asia ...
Cached Biology Technology:Angiotech launches e-commerce website that allows customers to order Quill(TM) SRS product line 2Angiotech launches e-commerce website that allows customers to order Quill(TM) SRS product line 3Angiotech launches e-commerce website that allows customers to order Quill(TM) SRS product line 4ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week 2ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week 3ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week 4ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week 5Pharma and Biotech Companies Plug into Singapore's Integrated Research Network 2Pharma and Biotech Companies Plug into Singapore's Integrated Research Network 3Pharma and Biotech Companies Plug into Singapore's Integrated Research Network 4Pharma and Biotech Companies Plug into Singapore's Integrated Research Network 5
(Date:4/24/2014)... Allan, PhD, a scientist at Western University and the ... spreads or metastasizes to the lung. , Breast cancer ... two cause of cancer-related deaths among women in North ... have a high success rate, but once the disease ... particular, the lung is one of the most common ...
(Date:4/24/2014)... at Ludwig-Maximilians-Universitaet (LMU) in Munich have identified the ... to discriminate between viral and endogenous RNAs in ... take control of cellular metabolism and hijack cellular ... process is dependent on viral RNA molecules that ... RNA viruses) and/or newly synthesized in the host ...
(Date:4/24/2014)... be improved with new insights into the make-up of ... the Amazon Basin have revealed unprecedented detail of the ... by comparing satellite maps with hundreds of field plots. ... more accurately the amount of carbon each tree can ... schemes, in which trees are given a cash value ...
Breaking Biology News(10 mins):New study helps to explain why breast cancer often spreads to the lung 2Viral infections: Identifying the tell-tale patterns 2Viral infections: Identifying the tell-tale patterns 3Amazon rainforest survey could improve carbon offset schemes 2
... states are invited to attend the annual meeting of ... Oct. 28 and 29 in Spokane, Wash. The ... policy and technology of carbon capture and storage (CCS). ... carbon sequestration technologies, the economics of CCS, regulatory and ...
... Zeitlinger, Ph.D., Stowers Institute Assistant Investigator, has been ... National Institutes of Health (NIH). Dr. Zeitlinger was ... million over five years. The awards enable recipients ... biomedical and behavioral science. "Nothing is ...
... assistant bioengineering professor at the UC San Diego Jacobs School ... tissue engineering. With a new $1.5 million New Innovator Award ... be able to do just that. , The awards, ... small number of new investigators who have exceptional creativity and ...
Cached Biology News:Julia Zeitlinger selected for NIH Director's New Innovator Award 2Generation innovation: Young UC San Diego bioengineer to use NIH grant to fuel tissue engineering 2Generation innovation: Young UC San Diego bioengineer to use NIH grant to fuel tissue engineering 3
... Immunogen KLH-conjugated, synthetic ... 54-75 (RRGPHRNPG-PGDDDGQRSRSSS) of mouse p19ARF. ... to amino acids 62-75. Clone ... Routinely evaluated by immunoblot. ...
Request Info...
Hybridization cassette for one slide...
Request Info...
Biology Products: